GILEAD SCIENCES, INC.
Close on Oct 19, 2026
- Market cap
- $190.27B
- P/E (TTM)
- –
- Dividend yield
- 2.06%
About Gilead Sciences
Biological Products, (No Diagnostic Substances), SIC 2836
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and delivers therapies targeting life-threatening medical conditions. The firm concentrates its commercial and clinical efforts primarily on virology, oncology, and liver diseases. Its portfolio comprises treatments for HIV management and prevention, hepatitis, COVID-19, and several cancers, as well as specialized cell therapies and antifungal solutions. Gilead provides these medicines to patients globally, commercializing them mainly through pharmaceutical wholesale distributors, specialty distributors, direct clinical promotion to healthcare providers, and regional commercial partnerships.
The company operates marketing subsidiaries and commercial sales infrastructure in more than 35 countries worldwide, with corporate headquarters located in Foster City, California. Gilead supports its international drug pipeline and supply chain through owned and leased facilities located across the United States, Ireland, Canada, and the Netherlands, which perform research, processing, packaging, and manufacturing. As of late 2025, the enterprise employs approximately 17,000 individuals across its global business operations.
Summary of the business section of Gilead Sciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- GILEAD SCIENCES, INC.
- Founded
- 1987
- Headquarters
- Foster City, CA
- Address
- 333 Lakeside Dr 94404
- Phone
- (650) 574-3000
- Website
- gilead.com
- Employees
- 17,000, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Mateo, California
Stock & identifiers
- Ticker
- GILD
- Exchange
- Nasdaq
- Shares outstanding
- 1.24B, Jul 31, 2026
- Public float
- $103.20B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Feb 27, 2013; 2-for-1, Jan 28, 2013; 2-for-1, Jun 25, 2007; 2-for-1, Sep 7, 2004; 2-for-1, Mar 8, 2002; 2-for-1, Feb 22, 2001
- SEC CIK
- 882095
- CUSIP
- 375558103
- ISIN
- US3755581036
- LEI
- 549300WTZWR07K8MNV44
- EIN
- 94-3047598
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Daniel Patrick O'Day | Chairman & CEO, Director | 585,913 |
| Erin Burkhart | SVP, Controllership | 2,223 |
| Andrew D. Dickinson | Chief Financial Officer | 164,096 |
| Johanna Mercier | Chief Comm & Corp Aff Officer | 116,684 |
| Wettan Keeley M. Cain | EVP Gen Counsel, Legal & Comp | 8,759 |
| Dietmar Berger | Chief Medical Officer | 19,785 |
| Deborah H. Telman | EVP, Corporate Affairs & GC | 79,641 |
| Diane E. Wilfong | Interim Corp Controller & CAO | 46,597 |
| Sandra Patterson | SVP, Controllership | 40,077 |
| Merdad Parsey | Chief Medical Officer | 84,621 |
| Anthony Welters | Director | 20,612 |
| Jeffrey Bluestone | Director | 10,066 |
| Kelly A. Kramer | Director | 4,144 |
| Ted W. Love | Director | 5,484 |
| Javier Rodriguez | Director | 13,364 |
| Harish Manwani | Director | 15,015 |
| Jacqueline K. Barton | Director | 27,202 |
| Sandra Horning | Director | 6,293 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. ODay | $28.44M | $63.26M | $9.25M | $255 | $125 |
| FY2024 Mr. ODay | $23.69M | $44.79M | $7.73M | $187 | $93 |
| FY2023 Mr ODay | $22.61M | $15.48M | $7.59M | $157 | $94 |
| FY2023 Mr. ODay | $22.61M | $15.48M | $7.59M | $157 | $94 |
| FY2022 Mr ODay | $21.62M | $54.97M | $7.87M | $161 | $90 |
| FY2022 Mr. ODay | $21.62M | $54.97M | $7.87M | $161 | $90 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, Gilead had approximately 17,000 employees.”
Corporate history
Events identified from SEC filings